Search for a trial

A Phase 2, Single dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

4.1 Primary• To estimate the Sensitivity and False Positive rate of OTL38 for malignancy detection during Near Infrared Imaging (NIR).• To assess the safety and tolerability of single intravenous doses of OTL384.2 Secondary• To assess the safety of…

Phase 1b study of safety and tolerability in patients treated with stereotactic radiotherapy combined with durvalumab and tremelimumab in stage 4 NSCLC

To assess safety and tolerability of the combination of SBRT and combined CTLA-4/PD-L1 inhibition. In addition immune modulatory effect of the combination of an ablative dose of radiotherapy to the primary tumor and response to durvalumab/…

An observational study to determine the pharmacokinetics of pemetrexed with and without hyperhydration during cisplatin administration (HYDRA).

The primary objective is to assess the impact of hyperhydration on pemetrexed pharmacokinetics. The secondary objective is to compare the performance of different renal function algorithms to predict pemetrexed pharmacokinetics.

A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)

The primary objective is to assess treatment with rovalpituzumab tesirine improves overall survival rate (OS) compared to topotecan in subjects with DLL3high SCLC who have first disease progression during or following front-line platinum based…

A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M

Primary objectiveTo assess the efficacy of the combination of osimertinib and bevacizumab versus osimertinib alone in terms of progression-free survival (PFS) assessed by RECIST 1.1.Secondary Objectives:To compare short and long term clinical…

A Phase 3, randomized, open label study of lorlatinib (PF 06463922) monotherapy versus crizotinib monotherapy in the first line treatment of patients with advanced ALK positive non small cell lung cancer

This study has been transitioned to CTIS with ID 2023-509169-19-00 check the CTIS register for the current data. To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival…

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as
Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with
Extensive Stage Small Cell Lung Cancer (MERU)

The primary objective of the study is to evaluate if rovalpituzumab tesirine improves progression-free and overall survival in subjects with extensive-stage SCLC who have ongoing clinical benefit (SD, PR, or CR) following the completion of 4 cycles…

A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC)

To assess the efficacy of durvalumab +tremelimumab + EP treatment compared with EP in terms of OS and the efficacy of durvalumab + EP treatment compared with EP in terms of OS

Tumormarkers in diagnostics and follow up of lungcarcinoma

This study aims to prospectively evaluate the diagnostic properties and clinical value of the protein tumor markers CEA, CA15.3, Cyfra21.1, HE4, NSE, proGRP en SCC and the molecular tumormarkers EGFR, ALK, KRAS and BRAF in diagnosing, and monitoring…

Combining SBRT and pembrolizumab in early stage non-small cell lungcancer patients planned for surgery: exploring safety and immunological proof of principle.

To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…

Imaging in Lifelines

The Imalife study aims to assess reference values of lung density, bronchial wall thickness, vascular calcification and lung nodules by quantitative low-dose CT. Secondarily, it aims to assess the relation of quantitative imaging biomarkers of the…

NL NVALT2017 / Translational research for immune modulating and targeted therapy in non-small cell lung cancer, an exploratory NVALT study

* To explore baseline predictive biomarkers for tumor response to immune modulating and targeted treatment in patients with NSCLC.* To develop biomarkers of therapy resistance to anti-PD-1 treatment in patients with NSCLC.* To explore patterns of…

Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients

Primary: Dose confirmation part: To establish the Maximum Tolerated Dose (MTD) and/or Recommended dose for expansion (RDE) of PDR001 with platinum-doublet chemotherapy in treatment naïve patients with PD-L1 unselected, advanced NSCLC of squamous or…

CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer, an exploratory study

Predictive value of patient specific KRAS mutation in ctDNA in serial blood samples (trajectories) and a durable clinical response to nivolumab.

CA209-762: Pilot study of fine needle aspiration (EUS/EBUS) versus histology for PD-L1 staining in lung cancer, a pilot study.

The primary objective for this study is to explore the options for a minimally invasive predictive test for selecting patients for the treatment with an anti-PD1/PD-L1 treatment. The secondary objective is to explore for which patients with PD-L1…

Characterization of Methylation Patterns in Lung Cancer (Lung-RND-001)

• Characterization of methylation patterns in blood samples and finding of methylation patterns that are unique to lung cancer.• Development of a molecular test for early diagnosis of lung cancer from a blood sample that will be more sensitive and…

The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'

Primary objective:To evaluate the area under the curve of afatinib compared to afatinib concomitantly used with esomeprazole and to afatinib used with esomeprazole 3 hours prior in patients with non-small cell lung cancer.Secondary objective:1.…

Companion biomarker development for MEDI4736 treated non-small-cell lung cancer patients using 89Zirconium-labeled MEDI4736 * a feasibility study

To assess the safety and biodistribution of 89Zr-MEDI4736 and its uptake in tumor and target irAE tissues.